1. Home
  2. PRLD

PRLD

Prelude Therapeutics Incorporated

Logo Prelude Therapeutics Incorporated

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-17-2024 11:27am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Founded: 2016 Country:
United States
United States
Employees: N/A City: WILMINGTON
Market Cap: 258.1M IPO Year: 2020
Target Price: $5.25 AVG Volume (30 days): 68.2K
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.02 EPS Growth: N/A
52 Week Low/High: $1.66 - $8.57 Next Earning Date: 05-06-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: